Grant: Master's Award: Canada Graduate Scholarships
University of Calgary
$17,500.00
Investigating the unique immunological and virological characteristics of chronic hepatitis B in pregnancy
EF 2019-20
Résumé
"Introduction: 250,000 Canadians have chronic hepatitis B (CHB). Individuals with CHB are at an increased risk for developing liver cancer. Liver cancer is the third leading cause of cancer related deaths worldwide. The virus that causes CHB is the hepatitis B virus (HBV). More than 90% of CHB cases are due to transmission of HBV from mother to child at birth. To prevent transmission, tenofovir (TDF, anti-viral medicine) is given in the third trimester. Individuals with CHB are closely monitored as current treatments like TDF cannot eliminate the virus. This can cause significant stress and stigma. Thus, it is crucial that we find a cure. We have observed that when pregnant women with CHB stopped TDF after birth, HBV levels decreased. This led to immune control of the infection. We hypothesize that immune restoration after birth and increase in anti-viral immune response from TDF stoppage will lead to a more robust control of HBV. Objectives: This study aims to assess: (1) immune responses, (2) changes in HBV replication, and (3) clinical outcomes in TDF treated and untreated pregnant women with CHB. Methods: As a part of an ongoing study at the Foothills Medical Center, we are currently enrolling 50 TDF treated and untreated pregnant women with CHB. The blood samples will be collected in early and late pregnancy and after birth. (1) To assess immune response, we will characterize different immune cells and associated proteins. (2) HBV markers will be quantified to monitor HBV replication and evolution. (3) To determine clinical outcomes to TDF, patient history and results of standard clinical tests for CHB and liver disease progression will be collected and analyzed. Significance: The results of this study will contribute towards the development of a novel cure for CHB."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
429087
Name
Patel Nishi H
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating the unique immunological and virological characteristics of chronic hepatitis B in pregnancy
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Chronic Hepatitis B; Cure; Hepatitis B Virus; Hepatocellular Carcinoma; Pregnancy
Abstract
"<strong>Introduction:</strong> 250,000 Canadians have chronic hepatitis B (CHB). Individuals with CHB are at an increased risk for developing liver cancer. Liver cancer is the third leading cause of cancer related deaths worldwide. The virus that causes CHB is the hepatitis B virus (HBV). More than 90% of CHB cases are due to transmission of HBV from mother to child at birth. To prevent transmission, tenofovir (TDF, anti-viral medicine) is given in the third trimester. Individuals with CHB are closely monitored as current treatments like TDF cannot eliminate the virus. This can cause significant stress and stigma. Thus, it is crucial that we find a cure. We have observed that when pregnant women with CHB stopped TDF after birth, HBV levels decreased. This led to immune control of the infection. <strong>We hypothesize that immune restoration after birth and increase in anti-viral immune response from TDF stoppage will lead to a more robust control of HBV. Objectives:</strong> This study aims to assess: (1) immune responses, (2) changes in HBV replication, and (3) clinical outcomes in TDF treated and untreated pregnant women with CHB. <strong>Methods:</strong> As a part of an ongoing study at the Foothills Medical Center, we are currently enrolling 50 TDF treated and untreated pregnant women with CHB. The blood samples will be collected in early and late pregnancy and after birth. (1) To assess immune response, we will characterize different immune cells and associated proteins. (2) HBV markers will be quantified to monitor HBV replication and evolution. (3) To determine clinical outcomes to TDF, patient history and results of standard clinical tests for CHB and liver disease progression will be collected and analyzed. <strong>Significance:</strong> The results of this study will contribute towards the development of a novel cure for CHB."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Patel, Nishi H
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~